Making Sense with Sam Harris - Subscriber Content cover image

Making Sense with Sam Harris - Subscriber Content

#377 - The Future of Psychedelic Medicine 2

Jul 26, 2024
Dr. Jennifer Mitchell, a UCSF neurology expert, and Dr. Sarah Abedi, a dedicated psychedelic researcher, discuss the evolving landscape of psychedelic medicine. They explore the promising potential of MDMA-assisted therapy for PTSD and the historical context of psychedelics, tracing their tumultuous past and recent resurgence. The conversation highlights the complexities of research, ongoing FDA approval hurdles, and the ethical considerations surrounding therapeutic practices. Ultimately, they envision a future where psychedelics provide innovative solutions for mental health treatment.
01:16:19

Podcast summary created with Snipd AI

Quick takeaways

  • Recent research shows MDMA can effectively treat PTSD, with about 70% of participants losing their diagnosis post-treatment, contrasting existing therapies.
  • The FDA's review process faces challenges like unblinding issues and allegations of therapist misconduct, highlighting the need for better oversight in psychedelic trials.

Deep dives

The Promise of Psychedelic Medicines for Mental Health

Research into psychedelic medications, particularly MDMA and psilocybin, shows significant promise in treating conditions like PTSD, anxiety, and depression. Studies indicate that approximately 70% of participants in MDMA trials for PTSD report losing their diagnosis after treatment, which starkly contrasts with existing therapies. The development of these drugs is hindered by historical stigmatization and funding challenges stemming from the war on drugs. Experts stress that unlocking funding and expanding research is crucial to bringing these therapies to clinical use.

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner